Tudor Investment Corp ET AL Cuts Position in Xeris Biopharma Holdings, Inc. $XERS

Tudor Investment Corp ET AL trimmed its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 83.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,994 shares of the company’s stock after selling 187,192 shares during the period. Tudor Investment Corp ET AL’s holdings in Xeris Biopharma were worth $309,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of XERS. CIBC Bancorp USA Inc. acquired a new stake in shares of Xeris Biopharma in the third quarter worth $133,000. Harvest Investment Services LLC raised its holdings in shares of Xeris Biopharma by 190.8% during the 3rd quarter. Harvest Investment Services LLC now owns 325,555 shares of the company’s stock valued at $2,650,000 after buying an additional 213,585 shares during the period. Caxton Associates LLP acquired a new position in shares of Xeris Biopharma during the third quarter worth $2,290,000. Dark Forest Capital Management LP purchased a new stake in shares of Xeris Biopharma during the third quarter worth about $1,113,000. Finally, Voloridge Investment Management LLC increased its position in shares of Xeris Biopharma by 4.0% during the third quarter. Voloridge Investment Management LLC now owns 1,034,553 shares of the company’s stock worth $8,421,000 after acquiring an additional 40,172 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock opened at $6.04 on Thursday. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19. Xeris Biopharma Holdings, Inc. has a 1 year low of $3.81 and a 1 year high of $10.08. The firm’s 50-day simple moving average is $6.39 and its 200-day simple moving average is $7.31. The firm has a market cap of $1.04 billion, a PE ratio of -603.40 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The firm had revenue of $85.81 million during the quarter, compared to analyst estimates of $86.00 million. Equities analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Transactions at Xeris Biopharma

In related news, insider John Patrick Shannon, Jr. sold 24,907 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $7.08, for a total transaction of $176,341.56. Following the completion of the transaction, the insider directly owned 2,705,346 shares in the company, valued at $19,153,849.68. This represents a 0.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin Mcculloch sold 15,000 shares of the firm’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $8.00, for a total value of $120,000.00. Following the completion of the sale, the insider owned 1,685,426 shares in the company, valued at $13,483,408. The trade was a 0.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 89,908 shares of company stock worth $648,515. 6.47% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on XERS. Weiss Ratings raised Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a report on Monday, March 2nd. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Finally, Barclays started coverage on Xeris Biopharma in a research note on Monday, December 8th. They set an “overweight” rating and a $9.00 target price for the company. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Xeris Biopharma currently has an average rating of “Moderate Buy” and an average price target of $10.80.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.